Clinical Trial Update: BI 2536 Second Line Monotherapy in SCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BI 2536 as second-line monotherapy for small cell carcinoma (small cell lung cancer) has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• BI-2536

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Small Cell | Phase 2 | Status: COMPLETED | Results posted: 2022-05-31